Biotech startups that raised Series C in China
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| QL Biopharma | Beijing | Series C | $44.7M | 2026-09-14 |
| AusperBio | Hangzhou | Series C | $120.0M | 2026-08-27 |
| Diyingjia Technology | Beijing | Series C | $3.0M | 2026-07-28 |
| Shengqiang Technology | Shenzhen | Series C | $13.7M | 2026-07-26 |
| Delova Biotech | Qixia | Series C | $88.6M | 2026-07-22 |
| Weikaier Pharmaceutical Technology | Nanjing | Series C | $29.6M | 2026-06-02 |
| YolTech Therapeutics | Minhang | Series C | $73.8M | 2026-05-29 |
| Zenitar | Chengdu | Series C | $86.0M | 2026-01-12 |
8 rows of the CSV in 5 of its 18 columns.
- The 160 biotech startups in China whose last round is Series C have raised $7.1B in total.
- 28 of them closed their most recent round in the last 12 months, $1.1B combined.
- The largest of those rounds is AusperBio's $120.0M Series C, dated August 2026.
- The most recent is Yudao Bio's $40.0M Series C on 15 September 2026.
- Legend Capital is an investor in 4 of them, more than any other fund.
- Health care is the most common other sector, with 142 companies (89%).
- 5% were founded in 2020 or later; the median founding year is 2015.
- The most common team size is 51 to 100 employees (27% of companies with a recorded size).
- 1 is a unicorn, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
24 of 160| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| QL Biopharma | QL Biopharma develops recombinant protein drugs to treat chronic metabolic diseases. | Biotech | Beijing | Series C | $44.7M | 2026-09-14 | $173.7M | Chengdu Science and Technology Venture Capital, TF Capital, Lichen Capital +1 | 101 to 250 | 2018 |
| AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Hangzhou | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, BioVenture, Hankang Capital +1 | 51 to 100 | 2019 |
| Diyingjia Technology | Diyingjia Technology develops artificial intelligence software for medical imaging and treatment applications. | Artificial intelligence | Beijing | Series C | $3.0M | 2026-07-28 | $32.3M | IDG Capital, Legend Capital, Microsoft Accelerator | 11 to 50 | 2017 |
| Shengqiang Technology | Shengqiang Technology researches, manufactures, and sells high-tech products. | Biotech | Shenzhen | Series C | $13.7M | 2026-07-26 | $13.7M | SDIC Venture Capital | 101 to 250 | 2013 |
| Delova Biotech | Delova Biotech develops treatments for pain management. | Biotech | Qixia | Series C | $88.6M | 2026-07-22 | $109.8M | Legend Capital, Peakview Capital, Hyfinity Investments +1 | 51 to 100 | 2017 |
| Weikaier Pharmaceutical Technology | Weikaier Pharmaceutical Technology conducts drug research, transfers generic drug technology, and produces and sells pharmaceuticals. | Biotech | Nanjing | Series C | $29.6M | 2026-06-02 | $120.4M | SDIC Venture Capital, Dyee Capital, Nanjing Innovation Capital Group +1 | 501 to 1,000 | 2010 |
| YolTech Therapeutics | YolTech Therapeutics combines LNP delivery with gene editing technology for biotechnology applications. | Biotech | Minhang | Series C | $73.8M | 2026-05-29 | $144.9M | K2VC, UnityVC, Decheng Capital +1 | 11 to 50 | 2021 |
| Zenitar | Zenitar conducts drug research and biomedical technology industrialization. | Biotech | Chengdu | Series C | $86.0M | 2026-01-12 | $155.7M | Si Chuan Venture Capital, Chengdu High-tech Ceyuan Capital, New Value Capital | 51 to 100 | 2019 |
| DP Technology | DP Technology applies AI to scientific research and industrial R&D challenges worldwide. | Artificial intelligence | Haidian | Series C | $113.9M | 2025-12-24 | $253.7M | Matrix Partners China, Qiming Venture Partners, Hillhouse Investment +1 | 101 to 250 | 2018 |
| Darwin Cell Biology | Darwin Cell Biology provides cell biotechnology services. | Biotech | Beijing | Series C | $27.9M | 2025-12-08 | $62.4M | Shijingshan Modern Innovation Industry Fund, Shanghai Yungu Investment | 11 to 50 | 2016 |
| Healsun Biopharm | Healsun Biopharm provides antibody and recombinant protein CRO and CDMO services. | Biotech | Hangzhou | Series C | $27.8M | 2025-11-19 | $101.3M | Yinxinggu Capital, Haitong Capital, Dongfang Jiafu +2 | 251 to 500 | 2015 |
| GRIT Biotechnology | GRIT Biotechnology develops tumor infiltrating lymphocyte immunotherapy for solid tumors. | Biotech | Shanghai | Series C | $84.0M | 2025-10-14 | $153.5M | Matrix Partners China, Hillhouse Investment, CICC +2 | 51 to 100 | 2019 |
| Yantai Lannacheng Biotechnology | Yantai Lannacheng Biotechnology develops Class I diagnostic medications. | Biotech | Yantai | Series C | $41.8M | 2025-07-20 | $103.8M | Shenzhen Capital Group, Qianhai Fund of Funds, Yuanhe Capital +1 | 1 to 10 | 2021 |
| Tianchen Biotechnology | Tianchen Biotechnology develops and sells medical products for ophthalmology. | Biotech | Tianjin | Series C | $27.8M | 2025-06-03 | $41.7M | CMB International Capital Corporation | 2018 | |
| LongBio Pharma | LongBio Pharma develops treatments for patients with complement and allergy diseases. | Biotech | Pudong | Series C | $28.9M | 2025-05-27 | $51.1M | Oriental Fortune Capital, Shanxi Securities Investment, Hefei Hongda +2 | 11 to 50 | 2020 |
| Zhiyi Pharmaceutics | Zhiyi Pharmaceutics researches and develops second-generation probiotics and live biotherapeutics. | Biotech | Guangzhou | Series C | $13.8M | 2024-03-28 | Shenzhen Capital Group, SDIC Venture Capital, Sinoking Capital | 51 to 100 | 2013 | |
| Hengruiyuan | Hengruiyuan develops immune cell-based medications for treating solid tumors. | Biotech | Songjiang | Series C | $14.1M | 2024-01-09 | $42.8M | Haiyuan Capital, Zhongke Kechuang | 501 to 1,000 | 2015 |
| DIAGENS | DIAGENS is a Hangzhou-based biotechnology firm that provides in-vitro diagnostic products and medical equipment. | Biotech | Hangzhou | Series C | $14.1M | 2023-12-29 | Shenzhen Guozhong Venture Capital Management, Haiyuan Capital, China Venture Capital HRVC +2 | 51 to 100 | 2014 | |
| Qitan Technology | Qitan Technology develops genome sequencing technology. | Biotech | Chengdu | Series C | $14.1M | 2023-12-28 | Hillhouse Investment, Gaorong Capital, CDH Investments +1 | 51 to 100 | 2016 | |
| Zenshine Pharma | Zenshine Pharma develops small molecule drugs for cancer and autoimmune diseases. | Biotech | Nanjing | Series C | $13.7M | 2023-10-13 | $28.7M | Matrix Partners China, Cybernaut Venture Capital, Kunlun Capital +2 | 11 to 50 | 2018 |
| LYNK Pharmaceuticals | LYNK Pharmaceuticals is a biotech company that discovers and develops new medicines. | Biotech | Hangzhou | Series C | $16.7M | 2023-09-21 | Legend Capital, Kaitai Capital, New Alliance Capital +2 | 11 to 50 | 2018 | |
| Canton Biologics | Canton Biologics provides biologics contract development and manufacturing outsourcing services. | Biotech | Guangzhou | Series C | $41.3M | 2023-09-13 | $41.7M | SDIC Venture Capital, Rongtuo Capital Management, Taipu Life Sciences Investment | 101 to 250 | 2016 |
| Konfoong Biotech International | Konfoong Biotech International is a biotechnology company. | Artificial intelligence | Ningbo | Series C | $14.9M | 2022-07-12 | Intel Capital, Yinxinggu Capital | 101 to 250 | 2011 | |
| MegaRobo Unicorn | MegaRobo is an AI and robotics company serving life sciences, clinical diagnosis, and applied chemistry. | Artificial intelligence | Beijing | Series C | $300.0M | 2022-06-15 | Innoangel Fund, Pavilion Capital | 1,001 to 5,000 | 2016 |
Table 1. Biotech startups that raised Series C in China: the 24 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 160.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Hangzhou | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, BioVenture, Hankang Capital +1 | 51 to 100 | 2019 |
| 2 | DP Technology | DP Technology applies AI to scientific research and industrial R&D challenges worldwide. | Artificial intelligence | Haidian | Series C | $113.9M | 2025-12-24 | $253.7M | Matrix Partners China, Qiming Venture Partners, Hillhouse Investment +1 | 101 to 250 | 2018 |
| 3 | Delova Biotech | Delova Biotech develops treatments for pain management. | Biotech | Qixia | Series C | $88.6M | 2026-07-22 | $109.8M | Legend Capital, Peakview Capital, Hyfinity Investments +1 | 51 to 100 | 2017 |
| 4 | Zenitar | Zenitar conducts drug research and biomedical technology industrialization. | Biotech | Chengdu | Series C | $86.0M | 2026-01-12 | $155.7M | Si Chuan Venture Capital, Chengdu High-tech Ceyuan Capital, New Value Capital | 51 to 100 | 2019 |
| 5 | YolTech Therapeutics | YolTech Therapeutics combines LNP delivery with gene editing technology for biotechnology applications. | Biotech | Minhang | Series C | $73.8M | 2026-05-29 | $144.9M | K2VC, UnityVC, Decheng Capital +1 | 11 to 50 | 2021 |
| 6 | QL Biopharma | QL Biopharma develops recombinant protein drugs to treat chronic metabolic diseases. | Biotech | Beijing | Series C | $44.7M | 2026-09-14 | $173.7M | Chengdu Science and Technology Venture Capital, TF Capital, Lichen Capital +1 | 101 to 250 | 2018 |
| 7 | Weikaier Pharmaceutical Technology | Weikaier Pharmaceutical Technology conducts drug research, transfers generic drug technology, and produces and sells pharmaceuticals. | Biotech | Nanjing | Series C | $29.6M | 2026-06-02 | $120.4M | SDIC Venture Capital, Dyee Capital, Nanjing Innovation Capital Group +1 | 501 to 1,000 | 2010 |
| 8 | Darwin Cell Biology | Darwin Cell Biology provides cell biotechnology services. | Biotech | Beijing | Series C | $27.9M | 2025-12-08 | $62.4M | Shijingshan Modern Innovation Industry Fund, Shanghai Yungu Investment | 11 to 50 | 2016 |
| 9 | Healsun Biopharm | Healsun Biopharm provides antibody and recombinant protein CRO and CDMO services. | Biotech | Hangzhou | Series C | $27.8M | 2025-11-19 | $101.3M | Yinxinggu Capital, Haitong Capital, Dongfang Jiafu +2 | 251 to 500 | 2015 |
| 10 | Shengqiang Technology | Shengqiang Technology researches, manufactures, and sells high-tech products. | Biotech | Shenzhen | Series C | $13.7M | 2026-07-26 | $13.7M | SDIC Venture Capital | 101 to 250 | 2013 |
Table 2. Biotech startups that raised Series C in China: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Legend Capital | Venture capital firm | Beijing, China | 4 | 2% | 2 | Diyingjia Technology, Delova Biotech |
| 2 | SDIC Venture Capital | Venture capital firm | Xicheng, China | 4 | 2% | 2 | Shengqiang Technology, Weikaier Pharmaceutical Technology |
| 3 | Matrix Partners China | Venture capital firm | Beijing, China | 4 | 2% | 1 | DP Technology |
| 4 | Decheng Capital | Venture capital firm | Menlo Park, United States | 3 | 2% | 1 | YolTech Therapeutics |
| 5 | Hillhouse Investment | Angel group | Singapore | 3 | 2% | 1 | DP Technology |
| 6 | Qianhai Fund of Funds | Private equity firm | Shanzhen, China | 3 | 2% | ||
| 7 | Oriental Fortune Capital | Venture capital firm | Shenzhen, China | 3 | 2% | ||
| 8 | Shenzhen Guozhong Venture Capital Management | Venture capital firm | Shenzhen, China | 3 | 2% | ||
| 9 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 2 | 1% | 2 | AusperBio, DP Technology |
| 10 | Hankang Capital | Venture capital firm | Shanghai, China | 2 | 1% | 1 | AusperBio |
| 11 | China Life Private Equity Investment | Private equity firm | Beijing, China | 2 | 1% | 1 | Weikaier Pharmaceutical Technology |
| 12 | Grand Flight Investment | Private equity firm | Shanghai, China | 2 | 1% | 1 | YolTech Therapeutics |
| 13 | Shanghai Biomedical Industrial Equity Investment Fund | Venture capital firm | Huangpu, China | 2 | 1% | 1 | Healsun Biopharm |
| 14 | Yinxinggu Capital | Venture capital firm | Hangzhou, China | 2 | 1% | 1 | Healsun Biopharm |
| 15 | Shenzhen Capital Group | Venture capital firm | Nanshan, China | 2 | 1% |
Table 3. Biotech startups that raised Series C in China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 142 | 89% | $6.5B |
| Software | 6 | 4% | $413.9M |
| Artificial intelligence | 5 | 3% | $313.9M |
| Hardware | 4 | 2% | |
| Cybersecurity | 1 | 1% |
Table 4. Biotech startups that raised Series C in China by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series C | 160 | 100% | $29.9M |
Table 5. Biotech startups that raised Series C in China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 6. Biotech startups that raised Series C in China by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| September 2026 | 2 | 7% | $84.7M |
| August 2026 | 3 | 11% | $157.1M |
| July 2026 | 7 | 25% | $234.2M |
| June 2026 | 3 | 11% | $73.8M |
| May 2026 | 2 | 7% | $123.8M |
| April 2026 | 2 | 7% | $101.7M |
| March 2026 | 1 | 4% | $14.5M |
| February 2026 | 2 | 7% | $65.0M |
| January 2026 | 1 | 4% | $86.0M |
| December 2025 | 4 | 14% | $156.0M |
| November 2025 | 1 | 4% | $27.8M |
Table 7. Biotech startups that raised Series C in China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 23 | 14% | $941.0M |
| 2025 | 24 | 15% | $725.7M |
| 2024 | 17 | 11% | $134.1M |
| 2023 | 19 | 12% | $311.3M |
| 2022 | 20 | 12% | $731.4M |
| 2021 | 25 | 16% | $1.9B |
Table 8. Biotech startups that raised Series C in China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2020 to 2022 | 8 | 5% |
| 2015 to 2019 | 80 | 50% |
| 2010 to 2014 | 42 | 26% |
| Before 2010 | 30 | 19% |
Table 9. Biotech startups that raised Series C in China by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 12 | 8% |
| 11 to 50 | 28 | 19% |
| 51 to 100 | 41 | 27% |
| 101 to 250 | 34 | 23% |
| 251 to 500 | 14 | 9% |
| 501 to 1,000 | 17 | 11% |
| 1,001 to 5,000 | 4 | 3% |
| 5,001 to 10,000 | 1 | 1% |
Table 10. Biotech startups that raised Series C in China by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series C and its headquarters is in China. On 16 November 2026 that is 160 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 24 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 160 rows: 40 have no round amount, 0 no city and 38 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in China whose last round is Series C are on the list?
- 160, in the file dated 16 November 2026. 28 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 160 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.